Analytical Data
-
Gene name
LCNL1
- Application
-
Alternative Names
LCNL1；Lipocalin-like 1 Protein
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q6ZST4
-
Expression Region
1-164aa
-
AA Sequence
MVGVVSDDQD FLDSKDTMKM AVVLVTPLGN GDLALKFGYP TPHGGCQKMD TTFTEGAVPG QFSNPAMALS DIRVAFSDYQ HFALLYLEMR KGGLRNQWLQ LYGGRAAGRR PRHPRFGSGM SPLCLHQPFL HAEGGTAGSW CLWPRVPAPP CPSLPLFAPP APSL
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
LCNL1, or Leucine-Cysteine-rich Nuclear Protein 1, has emerged as a significant focus of research due to its implicated roles in various biological processes, particularly in cell signaling, stress response, and transcriptional regulation. Discovered through genomic studies, LCNL1's unique structural features, characterized by a high content of leucine and cysteine residues, suggest its involvement in protein-protein interactions and cellular compartmentalization. Preliminary studies have indicated that LCNL1 may be linked to certain diseases, including cancer and neurodegenerative disorders, highlighting its potential as a biomarker or therapeutic target. The recombinant expression of LCNL1 allows for detailed functional assays and structural analyses, providing insights into its molecular mechanisms. Researchers are particularly interested in understanding how LCNL1 modulates cellular pathways under physiological and pathological conditions. Overall, the study of LCNL1 recombinant protein holds promise for advancing knowledge in molecular biology, with the potential to unlock new approaches for disease diagnosis and treatment.
